Vsiqq 120 mg/mL Solution for injection
PDF Leaflet Revision Date: 15 May 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of neovascular (wet) age-related macular degeneration and diabetic macular edema.
Dosage (summary)
6 mg (0.05 mL) by intravitreal injection; Wet AMD: every 4 weeks for 3 doses, then every 12 weeks; DME: every 6 weeks for 5 doses, then every 12 or 16 weeks.
Special Populations
- Hepatic impairment
- Renal impairment
- Elderly (u2265 65 years)
Pregnancy & Breastfeeding
Not recommended during pregnancy or breastfeeding due to potential risks.
Contraindications
- Hypersensitivity to brolucizumab
- Active ocular infections
- Active intraocular inflammation
Common side effects
- Reduced visual acuity
- Cataract
- Conjunctival haemorrhage
- Vitreous floaters
Counselling Points
- Use effective contraception during treatment and for 1 month after
- Monitor for visual disturbances post-injection
- Report any symptoms of intraocular inflammation immediately
Serious warnings
- Risk of endophthalmitis
- Retinal detachment
- Transient increases in intraocular pressure
Important Disclaimer
The Vsiqq 120 mg/mL Solution for injection professional information leaflet below is the property of Novartis South Africa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
